In regard to this research, Pop-Busui reported personal fees from Novo Nordisk during the conduct of the study, as well as Bayer and Novo Nordisk, and personal fees from Lexicon, Roche Diagnostic, and Vertex outside the submitted work
(PubMed) Caulfield LE, Zavaleta N, Shankar AH, Merialdi M
While no evidence suggests BPC-157 promotes cancer growth, precautionary consultation is appropriate
Those interruptions are often risky
Karlsson, T., Hadizadeh, F., Rask-Andersen, M., Johansson, & Ek, W
These incretin mimetics (and dual GIP/GLP-1 co-agonists ) have created a chronic care annuity model distinct from acute therapies